[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR054386A1 - Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina - Google Patents

Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina

Info

Publication number
AR054386A1
AR054386A1 ARP060102422A ARP060102422A AR054386A1 AR 054386 A1 AR054386 A1 AR 054386A1 AR P060102422 A ARP060102422 A AR P060102422A AR P060102422 A ARP060102422 A AR P060102422A AR 054386 A1 AR054386 A1 AR 054386A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
heteroaryl
halogen
Prior art date
Application number
ARP060102422A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR054386A1 publication Critical patent/AR054386A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) y ss N-oxidos, sales, solvatos e isomeros estereoquímicos aceptables desde el punto de vista farmacéutico, donde: Q es CH2 o un enlace directo; G es O, o S; X es N o CH; Z es NH, N8alquilo), o CH2; B es fenilo, cicloalquilo, heteroarilo, un heteroarilo benzo-fusionado de nueve a diez miembros, o un heterociclilo benzo-fusionado de nueve a diez miembros, R1 y R2 se seleccionan en forma independientemente de: (a-1) a (a-6), donde n es 1, 2, 3 o 4; Y es un enlace directo, O, S, NH, o N(alquilo); Ra es alcoxi, fenoxi, heteroarilo sustituido en forma opcional con R5, hidroxilo, alquilamino, dialquilamino, oxazolidinonilo sustituido en forma opcional con R5, pirrolidinonilo sustituido en forma opcional con R5, piperidinonilo sustituido en forma opcional con R5, piperazinil-2-ona sustituida en forma opcional con R5, heterodionilo cíclico sustituido en forma opcional con R5, heterociclilo sustituido en forma opcional con R5, escuarilo sustituido en forma opcional con R5, -COORy, -CONRwRx, -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, -SO2Ry, -NRwSO2Ry, -NRwSO2Rx, -SO3Ry, -OSO2NRwRx o -SO2NRwRx; Rw y Rx se seleccionan en forma independiente de: H, alquilo, alquenilo, aralquilo o heteroaralquilo, o Rw y Rx pueden tomarse juntos, en forma opcional, para formar un anillo de 5 a 7 miembros, que cntiene en forma opcional un resto con heteroátomo seleccionado de O, NH, N(alquilo), SO, SO2, o S; Ry se selecciona de: H, alquilo, alquenilo, cicloalquilo, fenilo, aralquilo, heteroaralquilo, o heteroarilo; R5 es 1, 2 o 3 sustituyentes selecionados de manera independiente de: halogeno, ciano, trifluorometilo, amno, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, - SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquil C1-4-N(alquilo)2, alquilo, -alquilC1-4-OH, -alquil C1-4-OCH3, -C(O)alquilC1-4-OH, -C(O)alquil C1-4-OCH3, dialquilamino o alquilamino; siempre que el mismo sustituyente R5 no esté presente más de una vez, salvo que dcho sustituyente R5 sea halogeno, hidroxilo, alcoxi o alquilo; Rbb es H, halogeno, alcoxi, dialquilamino, fenilo sustituido en forma opcional con R6, heteroarilo sustituido en forma opcional con R6, piperazinil-2-ona sustituida en forma opcional con R6, imidazolidinil-2-ona sustituida en forma opcional con R6, oxazolidinil-2-ona sustituida en forma opcional con R6, o heterociclilo sustituido en forma opcional con R6; R6 es 1, 2 o 3 sustituyentes seleccionados de manera independiente de: halogeno, ciano, trifluorometilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquilC1-4-N(alquilo)2, alquilo, -alquilC1-4-OH, -alquilC1-4-OCH3, -C(O)alquilC1-4- OH, -C(O)alquilC1-4-OCH3, dialquilamino o alquilamino, siempre que el mismo sustituyente R6 no esté presente más de una vez, salvo que dicho sustituyente R6 sea halogeno, hidroxilo, alcoxi o alquilo; Rc es heterociclilo sustituido en forma opcional con R7, o heteroarilo, y R7 es 1, 2 o 3 sustituyentes seleccionados de manera independiente de: halogeno, ciano, trifluorometilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquilC1-4- N(alquilo)2, alquilo, -alquilC1-4-OH, -alquilC1-4-OCH3, -C(O)alquilC1-4-OH, -C(O)alquilC1-4-OCH3, dialquilamino o alquilamino, siempre que el mismo sustituyente R7 no esté presente más de una vez, a no ser que dicho sustituyente R7 sea halogeno, hidroxilo, alcoxi o alquilo; R3 es uno o más sustituyentes seleccionados de manera independiente de: H siempre que Rbb no sea H, alquilo, alcoxi, halogeno, amino sustituido en forma opcional con R4, (alquilC1-2-OH, nitro, cicloalquilo sustituido en forma opcional con R4, heteroarilo sustituido en forma opcional con R4, alquilamino, heterociclilo sustituido en forma opcional con R4, alcoxiéter, -O(cicloalquilo), pirrolidinonilo sustituido en forma opcional con R4, fenoxi sustituido en forma opcional con R4, -CN, -OCHF2, -OCF3, -CF3, alquilo halogenado, heteroariloxi sustituido en forma opcional con R4, dialquilamino, -NHSO2alquilo o -SO2alquilo; donde R4 se selecciona de manera independiente de: halogeno, cian, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -CO2alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo o alquilamino.
ARP060102422A 2005-06-10 2006-06-09 Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina AR054386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
AR054386A1 true AR054386A1 (es) 2007-06-20

Family

ID=37038081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102422A AR054386A1 (es) 2005-06-10 2006-06-09 Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina

Country Status (18)

Country Link
US (1) US8071768B2 (es)
EP (1) EP1893598A1 (es)
JP (1) JP2009501135A (es)
KR (1) KR20080028912A (es)
AR (1) AR054386A1 (es)
AU (1) AU2006257945A1 (es)
BR (1) BRPI0611964A2 (es)
CA (1) CA2611242A1 (es)
CR (1) CR9652A (es)
EA (1) EA200800017A1 (es)
EC (1) ECSP077997A (es)
GT (1) GT200600251A (es)
IL (1) IL187692A0 (es)
NO (1) NO20080174L (es)
PE (1) PE20070014A1 (es)
TW (1) TW200716599A (es)
UY (1) UY29588A1 (es)
WO (1) WO2006135721A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8760507B2 (en) * 2008-08-05 2014-06-24 Inspectron, Inc. Light pipe for imaging head of video inspection device
EP2518064A1 (en) * 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
WO2012041872A1 (en) 2010-09-29 2012-04-05 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
KR101924247B1 (ko) 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
SI2922845T1 (sl) * 2012-11-20 2018-10-30 Merial, Inc. Antihelmintske spojine in sestavki ter postopek za njihovo uporabo
JP5887028B2 (ja) * 2013-10-16 2016-03-16 富士フイルム株式会社 含窒素複素環化合物の塩またはその結晶、医薬組成物およびｆｌｔ３阻害剤
JP2016540811A (ja) * 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
CN116574105A (zh) * 2018-09-27 2023-08-11 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
WO2020127738A1 (en) * 2018-12-21 2020-06-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Dna-pkcs inhibitors for increasing genome editing efficiency

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP0822788B1 (en) 1995-04-19 2002-09-04 Schneider (Usa) Inc. Drug release coated stent
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
DE69718306D1 (de) 1996-04-12 2003-02-13 Sumitomo Pharma Piperidinylpyrimidine derivate
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
CA2239227C (en) * 1996-10-01 2007-10-30 Kenji Matsuno Nitrogen-containing heterocyclic compounds
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
WO1999031086A1 (en) 1997-12-12 1999-06-24 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
DE60011612T2 (de) 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US6956039B2 (en) 2000-08-18 2005-10-18 Millennium Pharmaceuticals, Inc. Nitrogenous heterocylic compounds
WO2002016360A2 (en) 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
DE60113286T2 (de) 2000-10-17 2006-06-22 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
ATE310004T1 (de) 2000-12-12 2005-12-15 Neurogen Corp Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PL208283B1 (pl) 2001-12-27 2011-04-29 Theravance Pochodna indolinonu, sposób jej wytwarzania, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca i zastosowanie tej kompozycji
UA81619C2 (ru) 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004002960A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
WO2004043389A2 (en) 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
ATE425160T1 (de) 2002-12-18 2009-03-15 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SI1678166T1 (sl) 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
ECSP077997A (es) 2008-01-23
US8071768B2 (en) 2011-12-06
JP2009501135A (ja) 2009-01-15
IL187692A0 (en) 2008-08-07
TW200716599A (en) 2007-05-01
US20060281772A1 (en) 2006-12-14
WO2006135721A1 (en) 2006-12-21
AU2006257945A1 (en) 2006-12-21
EA200800017A1 (ru) 2008-08-29
BRPI0611964A2 (pt) 2009-01-27
UY29588A1 (es) 2006-10-02
EP1893598A1 (en) 2008-03-05
KR20080028912A (ko) 2008-04-02
NO20080174L (no) 2008-02-19
PE20070014A1 (es) 2007-03-08
CA2611242A1 (en) 2006-12-21
GT200600251A (es) 2007-01-12
CR9652A (es) 2008-09-09

Similar Documents

Publication Publication Date Title
AR054386A1 (es) Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina
AR053895A1 (es) Aminopirimidinas como moduladores de quinasas
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CO6251261A2 (es) Derivados de 1- 82-amino-2-oxoalquil)-n(1h-indazol-5-il)pirrolidina-3-carboxamida
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CO5601006A2 (es) Procedimiento para la preparacion de esteres de escopina
TW200833251A (en) Pesticidal compositions
ME00443B (me) Kristalni oblik tercijalne butilaminske soli perindoprila
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
NO20062549L (no) Substituerte arylpyrazoler anti-paresittmidlert
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
NI200800008A (es) Métodos para la neuroprotección
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
AR052885A1 (es) Metodos para el control del intervalo qt
MXPA05008584A (es) Compuestos heterociclicos utiles como activadores de nurr-1.
CO5680413A2 (es) Aminoacidos con afinidad por la proteina c2 delta

Legal Events

Date Code Title Description
FA Abandonment or withdrawal